Hyposmia in Parkinson's disease

Psychiatry and Clinical Neurosciences

Volumn 66, Issue 4, 2012, Pages 370-

  Alvarez, Maria Victoria ^a   Grogan, Patrick Mark ^b  

^a Center for Neurological Care and Research   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RASAGILINE;

FOLLOW UP; FUNCTION TEST; HUMAN; HYPOSMIA; LETTER; PARKINSON DISEASE; SMELLING; UNIFIED PARKINSON DISEASE RATING SCALE; UNIVERSITY OF PENNSYLVANIA SMELL IDENTIFICATION TEST;

HUMANS; INDANS; MONOAMINE OXIDASE INHIBITORS; OLFACTION DISORDERS; PARKINSON DISEASE;

EID: 84861535053     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2012.02339.x     Document Type: Letter

References (4)

1. Haehner A, Boesveldt S, Berendse HW, et al,. Prevalence of smell loss in Parkinson's disease: a multicenter study. Parkinsonism Relat. Disord. 2009; 15: 490-494.
2. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW,. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 2004; 56: 173-181.
3. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ,. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov. Disord. 2009; 24: 564-573.
4. Olanow CW, Rascol O, Hauser R, et al,. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 2009; 361: 1268-1278.